Stem Cell Clinic

Dr. Gerry Curatola Signs on as Advisory Board Member of Store-A-Tooth Dental Stem Cell Banking

By Stem Cell Clinic

Littleton, MA , MA (PRWEB) February 27, 2014

Provia Labs Store-A-Tooth, a Stem Cell Bank specializing in dental stem cell preservation, announces the appointment of Dr. Gerry Curatola, dentist, author and humanitarian best known for his clinical contributions in cosmetic dentistry and wellness, to their Advisory Board.

Dr. Curatola co-founded CS Bioscience Inc., a dental biotech company, and currently serves as its Chairman of the Board. The company performs research and development of pioneering natural therapeutics that promote oral health. In addition, Dr. Curatola is the founder of Rejuvenation Dentistry, a wellness-focused global network of dental practices, and the co-inventor and co-developer of REVITIN Oral Therapy. Dr. Curatola has private dental practices in both Manhattan and East Hampton, New York.

Following a lifelong model of humanitarian service, Dr. Curatola traveled to Andhra Pradesh, India at the invitation of Dr. Krishna Ajjarapu, founder of an orphanage and school in the region, to help establish a dental and medical clinic which will serve thousands of impoverished in this community. Closer to home, Dr. Curatola helped to establish the Pediatric Dental Fund of the Hamptons, a dental charity founded by local pediatrician, Dr. Gail Schoenfeld, which provides free dental care to needy children on Long Islands East End.

We are extremely fortunate to have Dr. Curatola as part of our team, said Provia Labs CEO Howard Greenman. His passion for the integration of oral health with overall health and wellness is aligned perfectly with the value of banking stem cells from teeth that ultimately will be useful for a patients overall health. Greenman adds, Most importantly, Gerry is a great guy, has an infectious personality and is truly on a mission to improve patients health - globally.

Dr Curatola, best known as Dr. Gerry, is a Celebrity Dentist and has contributed to numerous TV and radio programs including The Dr. Oz Show, The Martha Stewart Show, ABC News, FOX News, NBC, CBS, and CNN. I am excited about being an advisor to a world-class team like the one at Provia Labs, says Dr. Curatola. The decision to store dental stem cells now is a very important consideration for parents and their children who would otherwise discard this tissue. The future use of these valuable cells, stored in a robust, youthful state, is made possible by Provia Labs. Every dentist should provide their patients with the information to make an informed decision about banking their childs stem cells.

About Provia Laboratories, LLC Provia Laboratories, LLC (http://www.provialabs.com) is a health services company specializing in high quality stem cell biobanking (the collection, transport, processing, and cryogenic storage of biological specimens). Its dental stem cell banking service, Store-A-ToothTM, gives parents the option to store stem cells today to protect their childrens health tomorrow. Store-A-Tooth preserves stem cells from baby and wisdom teeth that would otherwise be discarded, so parents can be prepared for advances in stem cell therapies that someday may help treat conditions such as type 1 diabetes, spinal cord injury, heart attack, stroke, and neurological disorders like Parkinsons and Alzheimers.

For more information about Store-A-Tooth dental stem cell banking, please call 1-877-867-5753 or visit us at http://www.store-a-tooth.com or Like Store-A-Tooth at http://www.facebook.com/storeatooth.

Follow this link:
Dr. Gerry Curatola Signs on as Advisory Board Member of Store-A-Tooth Dental Stem Cell Banking

Purification, culture and multi-lineage differentiation of zebrafish neural crest cells

By Uncategorized

PUBLIC RELEASE DATE:

27-Feb-2014

Contact: Eric C. Liao cliao@partners.org Society for Experimental Biology and Medicine

Researchers at the Massachusetts General Hospital (MGH)/Harvard Medical School, Drs. Beste Kinikoglu and Yawei Kong, led by Dr. Eric C. Liao, cultured and characterized for the first time multipotent neural crest cells isolated from zebrafish embryos. This important study is reported in the February 2014 issue of Experimental Biology and Medicine. Neural crest is a unique cell population induced at the lateral border of the neural plate during embryogenesis and vertebrate development depends on these multipotent migratory cells. Defects in neural crest development result in a wide range of malformations, such as cleft lip and palate, and diseases, such as melanoma. Dr. Liao's laboratory uses zebrafish as a model vertebrate to study the genetic basis of neural crest related craniofacial malformations. Zebrafish has long been used to study early development and recently emerged as a model to study disease. "Development of in vitro culture of neural crest cells and reproducible functional assays will provide a valuable and complementary approach to the in vivo experiments in zebrafish" said Dr. Eric C. Liao, senior author of the study and an Assistant Professor of Surgery at MGH, and Principal Faculty at the Harvard Stem Cell Institute.

The team took advantage of the sox 10 reporter transgenic model to enrich and isolate the neural crest cells (NCCs), which were subsequently cultured under optimized culture conditions. Cultured NCCs were found to express major neural crest lineage markers such as sox10, sox9a, hnk1, p75, dlx2a, and pax3, and the pluripotency markers c-myc and klf4. The cells could be further differentiated into multiple neural crest lineages, contributing to neurons, glial cells, smooth muscle cells, melanocytes, and chondrocytes. Using the functional cell behavior assays that they developed, the team was able to assess the influence of retinoic acid, an endogenously synthesized, powerful, morphogenetic molecule, on NCC behavior. This study showed that retinoic acid had a profound effect on NCC morphology and differentiation, significantly inhibited proliferation and enhanced cell migration. The data implicate NCCs as a target cell population for retinoic acid and suggest that it plays multiple critical roles in NCC development.

"We hope that our novel neural crest system will be useful to gain mechanistic understanding of NCC development and for cell-based high-throughput drug screening applications" said Dr. Beste Kinikoglu, a postdoctoral fellow in Dr. Liao's laboratory and the study's first author. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Liao and colleagues have provided the first zebrafish embryo derived NCC pure population in vitro model for the study of neural crest development. I believe that this will be a valuable tool for this purpose".

###

Experimental Biology and Medicine is a journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit http://www.sebm.org. If you are interested in publishing in the journal please visit http://ebm.sagepub.com/.

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Follow this link:
Purification, culture and multi-lineage differentiation of zebrafish neural crest cells

Miami Stem Cell Treatment Center: Leaders in Stem Cell Treatment

By Stem Cell Treatment

(PRWEB) February 27, 2014

The Miami Stem Cell Treatment Center, PC, located in Miami, Ft. Lauderdale, and Boca Raton, Florida, announces a series of free public seminars on the use of stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief, and, Dr. Nia Smyrniotis, Medical Director.

The next upcoming seminars will be held on March 2nd and March 16th. The March 2nd lecture will be at the Hampton Inn Fort Lauderdale Downtown, 250 N. Andrews Blvd., Fort Lauderdale, Florida 33301, at 2pm. The March 16th lecture will be at the Comfort Suites Weston, 2201 N. Commerce Parkway, Weston, Florida 33326, at 2pm. You can, also, join Miami Stem Cell Treatment Center at the Health and Wellness Experience Expo presented by WPEC Channel 12 and the Sun-Sentinel on March 1st at Mizner Park Amphitheater, Boca Raton, Florida from 10am-5pm.

At the Miami Stem Cell Treatment Center, utilizing investigational protocols, adult adipose derived stem cells (ADSCs) can be deployed to improve patients quality of life with a number of degenerative conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (also called stromal vascular fraction (SVF)). Adipose tissue is exceptionally abundant in ADSCs. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body's natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys damaged cells. The Miami Stem Cell Treatment Center only uses autologous stem cells from a person's own fat no embryonic stem cells are used. Our current areas of study include: Heart Failure, Emphysema, COPD, Asthma, Parkinsons Disease, Stroke, Multiple Sclerosis, and orthopedic joint injections. For more information, or if someone thinks they may be a candidate for one of the stem cell protocols offered by Miami Stem Cell Treatment Center, they may contact Dr. Nia or Dr. Gionis directly at (561) 331-2999, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com.

About Miami Stem Cell Treatment Center: The Miami Stem Cell Treatment Center is an affiliate of the Irvine Stem Cell Treatment Center (Irvine, California) and the Cell Surgical Network (CSN). We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Research Protections; and the study is registered with http://www.Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information contact: Miami(at)MiamiStemCellsUSA(dot)com or visit our website: http://www.MiamiStemCellsUSA.com.

Go here to see the original:
Miami Stem Cell Treatment Center: Leaders in Stem Cell Treatment

Experimental Therapy Shows Promise Against Type of Adult Leukemia

By Uncategorized

By Amy Norton HealthDay Reporter

WEDNESDAY, Feb. 19, 2014 (HealthDay News) -- An experimental therapy that genetically tweaks the immune system may effectively treat a type of adult leukemia that often has a grim prognosis.

Researchers found that of 16 patients with advanced B-cell acute lymphoblastic leukemia (ALL), 88 percent went into remission after being treated with genetically altered versions of their own immune system cells.

The findings, reported Feb. 19 in the journal Science Translational Medicine, extend research published last spring on the first five patients to receive the treatment.

"First and foremost, we've shown that this isn't a fluke. This is a reliable result," said study senior author Dr. Renier Brentjens, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City.

There is still plenty of work to be done, he and other experts cautioned. The treatment, known as T-cell therapy, is not yet approved by the U.S. Food and Drug Administration and is only available in a research setting.

"We're still very much in the early stages of development," Brentjens said. But, he added, "this is potentially the first promising new therapy [for advanced B-cell ALL] in a long time."

Another expert agreed.

"The response rates are incredibly high," said Dr. David Porter, director of blood and marrow transplantation at the University of Pennsylvania's Abramson Cancer Center.

Porter, who was not involved in the study, has also been researching the T-cell therapy for advanced ALL, as well as another adult leukemia called chronic lymphocytic leukemia (CLL). The results for the ALL patients have not been published in a journal yet, but Porter said they've shown similar response rates.

Original post:
Experimental Therapy Shows Promise Against Type of Adult Leukemia

New neurons generated in brains, spinal cords of living adult mammals

By Stem Cell Medical Center

UT Southwestern Medical Center researchers created new nerve cells in the brains and spinal cords of living mammals without the need for stem cell transplants to replenish lost cells.

Although the research indicates it may someday be possible to regenerate neurons from the body's own cells to repair traumatic brain injury or spinal cord damage or to treat conditions such as Alzheimer's disease, the researchers stressed that it is too soon to know whether the neurons created in these initial studies resulted in any functional improvements, a goal for future research.

Spinal cord injuries can lead to an irreversible loss of neurons, and along with scarring, can ultimately lead to impaired motor and sensory functions. Scientists are hopeful that regenerating cells can be an avenue to repair damage, but adult spinal cords have limited ability to produce new neurons. Biomedical scientists have transplanted stem cells to replace neurons, but have faced other hurdles, underscoring the need for new methods of replenishing lost cells.

Scientists in UT Southwestern's Department of Molecular Biology first successfully turned astrocytes -- the most common non-neuronal brain cells -- into neurons that formed networks in mice. They now successfully turned scar-forming astrocytes in the spinal cords of adult mice into neurons. The latest findings are published today in Nature Communications and follow previous findings published in Nature Cell Biology.

"Our earlier work was the first to clearly show in vivo (in a living animal) that mature astrocytes can be reprogrammed to become functional neurons without the need of cell transplantation. The current study did something similar in the spine, turning scar-forming astrocytes into progenitor cells called neuroblasts that regenerated into neurons," said Dr. Chun-Li Zhang, assistant professor of molecular biology at UT Southwestern and senior author of both studies.

"Astrocytes are abundant and widely distributed both in the brain and in the spinal cord. In response to injury, these cells proliferate and contribute to scar formation. Once a scar has formed, it seals the injured area and creates a mechanical and biochemical barrier to neural regeneration," Dr. Zhang explained. "Our results indicate that the astrocytes may be ideal targets for in vivo reprogramming."

The scientists' two-step approach first introduces a biological substance that regulates the expression of genes, called a transcription factor, into areas of the brain or spinal cord where that factor is not highly expressed in adult mice. Of 12 transcription factors tested, only SOX2 switched fully differentiated, adult astrocytes to an earlier neuronal precursor, or neuroblast, stage of development, Dr. Zhang said.

In the second step, the researchers gave the mice a drug called valproic acid (VPA) that encouraged the survival of the neuroblasts and their maturation (differentiation) into neurons. VPA has been used to treat epilepsy for more than half a century and also is prescribed to treat bipolar disorder and to prevent migraine headaches, he said.

The current study reports neurogenesis (neuron creation) occurred in the spinal cords of both adult and aged (over one-year old) mice of both sexes, although the response was much weaker in the aged mice, Dr. Zhang said. Researchers now are searching for ways to boost the number and speed of neuron creation. Neuroblasts took four weeks to form and eight weeks to mature into neurons, slower than neurogenesis reported in lab dish experiments, so researchers plan to conduct experiments to determine if the slower pace helps the newly generated neurons properly integrate into their environment.

In the spinal cord study, SOX2-induced mature neurons created from reprogramming of astrocytes persisted for 210 days after the start of the experiment, the longest time the researchers examined, he added.

Originally posted here:
New neurons generated in brains, spinal cords of living adult mammals

Stem Cell Replacement Therapy for Common Foot Injuries Provides Rapid Healing

By Stem Cell Treatment

New York, New York (PRWEB) February 26, 2014

Adler Footcare of Greater New York is offering an advanced treatment option for chronic foot problems like plantar fasciitis, as well as common foot problems like Osteoarthritis, Achilles tendonitis and torn soft tissue.

In the past these conditions have been treated by physical therapy or orthotic therapy, but the results have often been poor, leaving patients continuing to struggle with the pain. With stem cell replacement therapy, the treatment of these conditions is proving far more effective and long lasting than traditional treatments.

At Adler Footcare we use live birth stem cells which are introduced into the affected area. Stem cells are used by many physicians to treat a broad variety of conditions because of their ability to either replicate themselves, or change into the cell type that is needed to repair the tissue that has been damaged. When a patient comes in for stem cell therapy, the affected area is carefully measured so the stem cells can be delivered directly to the area that needs the treatment.

The Joint Commission accredited Podiatric OR of Midtown Manhattan housed within Adler Footcare is designed to facilitate advanced treatments such as Stem Cell Replacement Therapy to all their patients.

With stem cell treatment we are finding that patients heal much faster and are able to return to their normal activities much sooner than with traditional treatment options, said Dr. Darline Kulhan, podiatric surgeon at Adler Footcare. Recovery time depends on each individual patients medical diagnosis and overall general health.

Treatments using stem cells have been used by physicians for over 100 years. Stem Cell Replacement Therapy is covered by commercial insurance and Medicare, and is approved and regulated by the FDA. The product is tested and screened by medical professionals to eliminate the potential of any communicable diseases.

To learn more about Stem Cell Replacement Therapy or to schedule a consultation with a New York podiatrist at Adler Footcare, call (212) 704-4310 or visit http://www.mynycpodiatrist.com.

About Adler Footcare New York

Dr. Jeffrey L. Adler, Medical/Surgical Director and owner of Adler Footcare New York has been practicing podiatric medicine since 1979 and has performed thousands of foot and ankle surgeries. Dr. Adler is board certified in Podiatric Surgery and Primary Podiatric Medicine by the American Board of Multiple Specialties in Podiatry. Dr. Adler is also a Professor of Minimally Invasive Foot Surgery for the Academy of Ambulatory Foot and Ankle Surgeons. As one of only several in the country who perform minimally invasive podiatric surgery, Dr. Adlers patients enjoy significantly reduced recovery times.

Follow this link:
Stem Cell Replacement Therapy for Common Foot Injuries Provides Rapid Healing

Learning About Cancer by Studying Stem Cells

By Stem Cell Medicine

Contact Information

Available for logged-in reporters only

Newswise Normally, when a cell becomes damaged or doesnt divide properly, the bodys natural recycling process breaks it down and it dies. Sometimes, though, the damage is to the genes that control a cell, and the result is out-of-control division. When this happens, a cancer cell is born.

New insights into how cancer cells arise and develop into tumors have come from researchers funded by the National Institutes of Health. Some of them are exploring the process by studying stem cells.

Modeling Early Pancreatic Cancer

Despite decades of progress in the detection, treatment and prevention of many types of cancer, the long-term survival rate for pancreatic cancer remains very low. One reason is that pancreatic cancer rarely produces symptoms until it has spread in the body.

The late stage at diagnosis also poses problems for researchers who want to study the early development of pancreatic cancer, according to Kenneth Zaret of the University of Pennsylvania School of Medicine. Thats because pancreatic cancer cells taken from people and then used to form tumors in animal models immediately produce the aggressive, advanced cancers from which they were derived.

Zarets lab has focused on understanding how transcription factors-proteins that control which genes in a cell are expressed-work in stem cells. His team recently explored the idea of reprogramming cancer cells so they act like embryonic stem cells, which can become just about any type of cell in the body. Because transcription factors in embryonic stem cells guide early organ development, the researchers thought that forcing cancer cells back to an embryonic state might allow the transcription factors to reproduce the early stages of cancer. This could then provide a model for studying the early development of pancreatic cancer.

Using tumor tissue from people with pancreatic cancer, Zaret and his colleagues succeeded in turning a sample of cancer cells back to an early, stem cell-like state. When used to create tumors in mice, these so-called induced pluripotent stem (iPS) cells formed early stage tumors and slowly progressed to invasive disease.

The human tumors grown in mice also secreted a wide range of proteins that are indicative of cell networks known to drive pancreatic cancer progression, as well as some not previously known to be associated with the disease. Were setting up collaborations to test these markers for their utility in screening human blood samples and see if they function as markers for detecting or predicting pancreatic cancer in humans, said Zaret.

The rest is here:
Learning About Cancer by Studying Stem Cells

Researchers Generate New Neurons in Brains, Spinal Cords of Living Adult Mammals Without the Need of Stem Cell …

By Stem Cell Medical Center

Contact Information

Available for logged-in reporters only

Newswise DALLAS, Feb. 25, 2014 UTSouthwestern Medical Center researchers created new nerve cells in the brains and spinal cords of living mammals without the need for stem cell transplants to replenish lost cells.

Although the research indicates it may someday be possible to regenerate neurons from the bodys own cells to repair traumatic brain injury or spinal cord damage or to treat conditions such as Alzheimers disease, the researchers stressed that it is too soon to know whether the neurons created in these initial studies resulted in any functional improvements, a goal for future research.

Spinal cord injuries can lead to an irreversible loss of neurons, and along with scarring, can ultimately lead to impaired motor and sensory functions. Scientists are hopeful that regenerating cells can be an avenue to repair damage, but adult spinal cords have limited ability to produce new neurons. Biomedical scientists have transplanted stem cells to replace neurons, but have faced other hurdles, underscoring the need for new methods of replenishing lost cells.

Scientists in UTSouthwesterns Department of Molecular Biology first successfully turned astrocytes the most common non-neuronal brain cells into neurons that formed networks in mice. They now successfully turned scar-forming astrocytes in the spinal cords of adult mice into neurons. The latest findings are published today in Nature Communications and follow previous findings published in Nature Cell Biology.

Our earlier work was the first to clearly show in vivo (in a living animal) that mature astrocytes can be reprogrammed to become functional neurons without the need of cell transplantation. The current study did something similar in the spine, turning scar-forming astrocytes into progenitor cells called neuroblasts that regenerated into neurons, said Dr. Chun-Li Zhang, assistant professor of molecular biology at UTSouthwestern and senior author of both studies.

Astrocytes are abundant and widely distributed both in the brain and in the spinal cord. In response to injury, these cells proliferate and contribute to scar formation. Once a scar has formed, it seals the injured area and creates a mechanical and biochemical barrier to neural regeneration, Dr. Zhang explained. Our results indicate that the astrocytes may be ideal targets for in vivo reprogramming.

The scientists' two-step approach first introduces a biological substance that regulates the expression of genes, called a transcription factor, into areas of the brain or spinal cord where that factor is not highly expressed in adult mice. Of 12 transcription factors tested, only SOX2 switched fully differentiated, adult astrocytes to an earlier neuronal precursor, or neuroblast, stage of development, Dr. Zhang said.

In the second step, the researchers gave the mice a drug called valproic acid (VPA) that encouraged the survival of the neuroblasts and their maturation (differentiation) into neurons. VPA has been used to treat epilepsy for more than half a century and also is prescribed to treat bipolar disorder and to prevent migraine headaches, he said.

Link:
Researchers Generate New Neurons in Brains, Spinal Cords of Living Adult Mammals Without the Need of Stem Cell ...

Kerry Simon finishes second round of stem-cell treatments, finalizes plans for MSA benefit Thursday

By Stem Cell Clinic

Cashman Photography

Kerry Simon and Sammy Hagar celebrate the second anniversary of KGB (Kerrys Gourmet Burgers) in Harrahs on Saturday, June 2,2012.

By Robin Leach (contact)

Monday, Feb. 24, 2014 | 4:07 p.m.

Iron Chef America winner Kerry Simon wrapped up his second round of stem-cell transplants Sunday at the Mayo Clinic in Rochester, Minn., and returns here today to put the final touches on his Fight MSA fundraiser Thursday at our downtown Keep Memory Alive event center at the Cleveland Clinic Lou Ruvo Center for Brain Health.

Chef Kerry is courageously battling Multiple System Atrophy, for which there is no treatment or cure. My colleague John Katsilometes story of Kerrys bravery was posted early Sunday.

Kerrys business partner Elizabeth Blau told me: Kerry is in great spirits and wanted to express his most sincere gratitude to everyone who has worked so hard on putting together the event. He is incredibly excited. We are four days out from our event, and Kerry thanks everyone for the herculean efforts that have gone into putting it together in such a short period of time.

We still have some tickets to sell for the last-minute push. We are getting a large number of requests for comped tickets from celebrities, people who have donated auction items, the media, and the list goes on. We are extremely grateful to everyone who has contributed even in the smallest of ways, but there are no comp tickets to this event.

There is no Kerry Simon guest list! Everyone on this committee has expended the greatest efforts and bought their own tickets to keep operational costs as low as possible and secured hundreds of auction items to make sure every dollar raised goes to effectively Fight MSA.

Oscar-nominated actor Bill Murray, a close friend of Kerrys, will MC the buffet party with star chefs Jean-Georges Vongerichten, Daniel Boulud, Michael Mina, Rick Moonen, Charlie Palmer, Barry Dakake and in concert Sammy Hagar, Vince Neil, Slash, Todd Rundgren, Alice Cooper, Lisa Loeb and System of a Downs John Dolmayan.

See the original post here:
Kerry Simon finishes second round of stem-cell treatments, finalizes plans for MSA benefit Thursday

RoosterBio Inc, a Frederick Maryland Biotech Startup, Achieves Rapid Traction with Product Launch and Fundraising …

By Uncategorized

Frederick, MD (PRWEB) February 25, 2014

RoosterBio Inc is a new biotech start-up supplying human bone marrow-derived Mesenchymal Stem Cells (hBM-MSC) for tissue engineering research and stem cell-based product development into the high growth Synthetic Biology and Regenerative Medicine fields. RoosterBio, Inc. initiated laboratory operations in October, 2013, and has achieved the critical milestone of first product shipment to paying customers in just four short months. In addition to the early validation of their business model and rapidly generating revenue, Roosterbio has raised over 250K in seed investment and are actively seeking funds via AngelList (https://angel.co/roosterbio).

RoosterBio credits their quick-to-market accomplishments to hyper-efficient operations and the passion that the RoosterBio team shares in their desire to assist tissue engineers and cell therapists to accelerate life-saving technologies into the clinic. Our laser focus coupled with operational excellence has enabled us to reach these milestones; we will delight our customers with our product offering, says Chief Operating Officer, Dr. Uplaksh Kumar. The RoosterBio teams extensive experience sourcing raw materials, manufacturing stem cell products, and controlling for high quality with best-in-class characterization techniques has allowed them to successfully launch their flagship hBM-MSC product quickly and efficiently.

Dr. Jon Rowley, RoosterBios Chief Executive said I cant express how proud I am of our small, highly dedicated team that worked tirelessly to get our first products designed, manufactured, quality tested, released, and just as importantly sold and shipped to our first paying customers. This was truly a team effort that couldnt have been done without each and every person at RoosterBio.

Having spent years as cell and tissue technologists, the RoosterBio team has an intimate understanding of the pain points surrounding the generation of large numbers of robust, reproducible, standardized cells for research and product development purposes. RoosterBio products are designed to solve this problem and they believe that high volume and affordable cellular raw materials will kick-start the cell-based medical product revolution.

Dr. Sarah Griffiths, a Researcher at Georgia Tech in Atlanta, believes that RoosterBios MSCs will do exactly that, and was anxiously awaiting receipt of the product. "We are excited to receive the first shipment of RoosterBios product. The potential to generate large stocks of MSCs in a short period of time will be a tremendous advantage to the progress of our research."

Researchers in the fields of Synthetic Biology and Regenerative Medicine, such as Dr. Griffiths, will use RoosterBios MSCs to develop new medical therapies to provide treatments for degenerative diseases such as Parkinsons and Alzheimers diseases, or to repair or replace tissue after a catastrophic injury such as traumatic bone and cartilage injury, spinal cord damage, heart attack, or significant burns.

RoosterBios current focus is to supply high volume research-grade cells manufactured with processes consistent with current Good Manufacturing Practices (cGMP). They are rapidly approaching their next milestones by laying the groundwork for initiating production of clinical-grade cells to be used in translational R&D and clinical studies.

About RoosterBio RoosterBio is focused on building a robust and sustainable Regenerative Medicine industry. Our products are affordable and standardized primary cells and media, manufactured and delivered with highest quality and in formats that simplify product development efforts. RoosterBio products are made with care in Frederick, MD, and will accelerate the translation of cell therapy and tissue engineering technologies into the clinic.

Read the original:
RoosterBio Inc, a Frederick Maryland Biotech Startup, Achieves Rapid Traction with Product Launch and Fundraising ...

→←